J-Code information available Click here for more details
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.1
LIBTAYO (cemiplimab-rwlc) Injection is a clear–to–slightly opalescent, colorless–to–pale yellow solution that may contain trace amounts of translucent-to-white particles.
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light. Do not freeze or shake.
LIBTAYOhcp.com or 1.877.LIBTAYO (1.877.542.8296),(1.877.542.8296), option 1
| Product information | |
|---|---|
| How supplied | 350-mg/7-mL (50 mg/mL) solution in a single-dose vial |
| Quantity and units per case | 1 vial per carton/24 cartons per case |
| NDC | 61755-008-01 (350 mg/7 mL) |
| HCPCS codes | J9119 - Injection, cemiplimab-rwlc, 1 mg |
| GTIN | 00361755008013 (350-mg/7-mL case) 00361755008018 (350-mg/7-mL carton) |
| UPC | 361755008018 (350 mg/7 mL) |
| LIBTAYO product information sheet | |
| LIBTAYO dosage and immune-mediated adverse reactions (imARs) guide | |
| LIBTAYO patient discussion guide | |
| LIBTAYO patient discussion guide (Spanish) | |
| LIBTAYO patient wallet card | |
| LIBTAYO patient brochure |
